Karyopharm Therapeutics (NASDAQ:KPTI) Receives “Outperform” Rating from Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $3.00 target price on the stock. Royal Bank of Canada’s price target indicates a potential upside of 380.00% from the stock’s previous close.

A number of other equities analysts also recently weighed in on KPTI. Piper Sandler boosted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI traded up $0.03 during trading hours on Thursday, hitting $0.63. 275,500 shares of the company traded hands, compared to its average volume of 830,288. The stock has a market capitalization of $78.87 million, a price-to-earnings ratio of -0.55 and a beta of 0.06. Karyopharm Therapeutics has a twelve month low of $0.53 and a twelve month high of $1.70. The business’s 50-day moving average is $0.67 and its 200-day moving average is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. Analysts predict that Karyopharm Therapeutics will post -0.83 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of large investors have recently added to or reduced their stakes in KPTI. Velan Capital Investment Management LP acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $27,000. Focus Partners Wealth acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at about $31,000. TD Waterhouse Canada Inc. acquired a new position in Karyopharm Therapeutics during the fourth quarter worth about $32,000. Two Sigma Advisers LP raised its holdings in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after buying an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).